217 related articles for article (PubMed ID: 23395317)
21. Liver-specific agents for contrast-enhanced MRI: role in oncological imaging.
Thian YL; Riddell AM; Koh DM
Cancer Imaging; 2013 Dec; 13(4):567-79. PubMed ID: 24434892
[TBL] [Abstract][Full Text] [Related]
22. Gadoxetic acid disodium-enhanced magnetic resonance imaging for biliary and vascular evaluations in preoperative living liver donors: comparison with gadobenate dimeglumine-enhanced MRI.
Lee MS; Lee JY; Kim SH; Park HS; Kim SH; Lee JM; Han JK; Choi BI
J Magn Reson Imaging; 2011 Jan; 33(1):149-59. PubMed ID: 21182133
[TBL] [Abstract][Full Text] [Related]
23. MultiHance: help or hype?
Bartolozzi C; Spinazzi A
J Comput Assist Tomogr; 1999 Nov; 23 Suppl 1():S151-9. PubMed ID: 10608411
[TBL] [Abstract][Full Text] [Related]
24. Contrast-enhanced MR imaging of the liver.
Saini S
Radiology; 1992 Jan; 182(1):12-4. PubMed ID: 1727273
[No Abstract] [Full Text] [Related]
25. MRI features of inflammatory hepatocellular adenomas on hepatocyte phase imaging with liver-specific contrast agents.
Thomeer MG; Willemssen FE; Biermann KK; El Addouli H; de Man RA; Ijzermans JN; Dwarkasing RS
J Magn Reson Imaging; 2014 May; 39(5):1259-64. PubMed ID: 23897798
[TBL] [Abstract][Full Text] [Related]
26. The value of gadobenate dimeglumine-enhanced hepatobiliary-phase MR imaging for the differentiation of scirrhous hepatocellular carcinoma and cholangiocarcinoma with or without hepatocellular carcinoma.
Jeon TY; Kim SH; Lee WJ; Lim HK
Abdom Imaging; 2010 Jun; 35(3):337-45. PubMed ID: 19350315
[TBL] [Abstract][Full Text] [Related]
27. Enhancement of liver parenchyma after injection of hepatocyte-specific MRI contrast media: a comparison of gadoxetic acid and gadobenate dimeglumine.
Filippone A; Blakeborough A; Breuer J; Grazioli L; Gschwend S; Hammerstingl R; Heinz-Peer G; Kittner T; Laghi A; Leen E; Lencioni R; Lucidarme O; Remplik P; Robinson PJ; Ruehm SG; Schaefer F; Stoupis C; Tombach B; Valette PJ; Zech CJ; Huppertz A
J Magn Reson Imaging; 2010 Feb; 31(2):356-64. PubMed ID: 20099349
[TBL] [Abstract][Full Text] [Related]
28. [MRT of the liver. Clinical significance of nonspecific and liver-specific MRT contrast agents].
Ba-Ssalamah A; Happel B; Kettenbach J; Dirisamer A; Wrba F; Längle F; Schima W
Radiologe; 2004 Dec; 44(12):1170-84. PubMed ID: 15551031
[TBL] [Abstract][Full Text] [Related]
29. [Manganese-DPDP in the MR tomography of malignant liver tumors. The initial results with a new hepatobiliary contrast agent].
Steudel A; Layer G; Kraheck H; Hartlapp J; Reiser M
Rofo; 1992 May; 156(5):460-4. PubMed ID: 1596550
[TBL] [Abstract][Full Text] [Related]
30. Liver lesion characterization: the wrong choice of contrast agent can mislead the diagnosis of hemangioma.
Pradella S; Lucarini S; Colagrande S
AJR Am J Roentgenol; 2012 Nov; 199(5):W662. PubMed ID: 23096214
[No Abstract] [Full Text] [Related]
31. Diagnosis of focal nodular hyperplasia with MRI: multicenter retrospective study comparing gadobenate dimeglumine to gadoxetate disodium.
Gupta RT; Iseman CM; Leyendecker JR; Shyknevsky I; Merkle EM; Taouli B
AJR Am J Roentgenol; 2012 Jul; 199(1):35-43. PubMed ID: 22733891
[TBL] [Abstract][Full Text] [Related]
32. MR imaging of benign and malignant biliary conditions.
Costello JR; Kalb B; Chundru S; Arif H; Petkovska I; Martin DR
Magn Reson Imaging Clin N Am; 2014 Aug; 22(3):467-88. PubMed ID: 25086940
[TBL] [Abstract][Full Text] [Related]
33. Hepatic hemangiomas: difference in enhancement pattern on 3T MR imaging with gadobenate dimeglumine versus gadoxetate disodium.
Gupta RT; Marin D; Boll DT; Husarik DB; Davis DE; Feuerlein S; Merkle EM
Eur J Radiol; 2012 Oct; 81(10):2457-62. PubMed ID: 22138122
[TBL] [Abstract][Full Text] [Related]
34. Hepatocellular tumors: characterization with Mn-DPDP-enhanced MR imaging.
Rofsky NM; Weinreb JC; Bernardino ME; Young SW; Lee JK; Noz ME
Radiology; 1993 Jul; 188(1):53-9. PubMed ID: 8390072
[TBL] [Abstract][Full Text] [Related]
35. Comparison of Gd-Bz-TTDA, Gd-EOB-DTPA, and Gd-BOPTA for dynamic MR imaging of the liver in rat models.
Jaw TS; Chen SH; Wang YM; Hsu JS; Kuo YT; Chiu YY; Tsai KB; Hsieh TJ; Liu GC
Kaohsiung J Med Sci; 2012 Mar; 28(3):130-7. PubMed ID: 22385605
[TBL] [Abstract][Full Text] [Related]
36. [The clinical value of Mn-DPDP: a new paramagnetic hepatobiliary contrast medium for magnetic resonance tomography of the liver].
Vogl TJ; Hamm B; Schnell B; Eibl-Eibesfeldt B; Steiner S; Lissner J
Rofo; 1991 Dec; 155(6):568-74. PubMed ID: 1764599
[TBL] [Abstract][Full Text] [Related]
37. Focal nodular hyperplasia: typical and atypical MRI findings with emphasis on the use of contrast media.
Marin D; Brancatelli G; Federle MP; Lagalla R; Catalano C; Passariello R; Midiri M; Vilgrain V
Clin Radiol; 2008 May; 63(5):577-85. PubMed ID: 18374723
[TBL] [Abstract][Full Text] [Related]
38. Volumetric mangafodipir trisodium-enhanced cholangiography to define intrahepatic biliary anatomy.
Lee VS; Rofsky NM; Morgan GR; Teperman LW; Krinsky GA; Berman P; Weinreb JC
AJR Am J Roentgenol; 2001 Apr; 176(4):906-8. PubMed ID: 11264075
[No Abstract] [Full Text] [Related]
39. Contrast enhanced liver MRI in patients with primary sclerosing cholangitis: inverse appearance of focal confluent fibrosis on delayed phase MR images with hepatocyte specific versus extracellular gadolinium based contrast agents.
Husarik DB; Gupta RT; Ringe KI; Boll DT; Merkle EM
Acad Radiol; 2011 Dec; 18(12):1549-54. PubMed ID: 21958599
[TBL] [Abstract][Full Text] [Related]
40. Cholangiocarcinoma in Cirrhosis: Value of Hepatocyte Specific Magnetic Resonance Imaging.
Piscaglia F; Iavarone M; Galassi M; Vavassori S; Renzulli M; Forzenigo LV; Granito A; Salvatore V; Sangiovanni A; Golfieri R; Colombo M; Bolondi L
Dig Dis; 2015 Oct; 33(6):735-44. PubMed ID: 26488875
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
